SCHEMBL7188875

SCHEMBL7188875

CCOc1ccc(PC(=O)c2c(C)cccc2C)cc1.[LiH]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
NQO1 P15559 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
PKM P14618 3/20 0.41
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LTA4H P09960 1/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
TP53 P04637 2/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
NFKB1 P19838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189820 0.91 MAPT (0.41) PARP10ALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL7185396 0.89 PPARG (0.44) SMN1; SMN2MAPTLMNATSHRLTA4H
SCHEMBL7175408 0.89 L3MBTL1 (0.44) ALDH1A1SMN1; SMN2KMT2AMAPTLMNA
SCHEMBL7185514 0.88 FFAR1 (0.43) SMN1; SMN2KMT2ALMNAMEN1TDP1
SCHEMBL7186887 0.87 ALDH1A1 (0.41) PARP10ALDH1A1GAANQO1SMN1; SMN2
SCHEMBL7179346 0.86 NR5A1 (0.48) TSHRLTA4HTP53
SCHEMBL7190132 0.85 TAS1R3 (0.44) PARP10ALDH1A1NQO1SMN1; SMN2KMT2A
SCHEMBL7182620 0.85 NR5A1 (0.50) TSHRLTA4HTP53
SCHEMBL7185510 0.85 NR1H4 (0.40) ALDH1A1KMT2AMAPTMEN1TP53
SCHEMBL7188657 0.85 L3MBTL1 (0.42) MAPTPKMLMNARAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 PARP10 1658/4885ALDH1A1 3416/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 PARP10 1147/4885ALDH1A1 3984/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.